These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 30716503)

  • 1. Long-Term Effects of Intracapsular Debulking and Adjuvant Somatostatin Analogs for Growth Hormone-Secreting Pituitary Macroadenoma: 10 Years of Experience in a Single Institute.
    Shen SC; Shen CC; Pu TW; Cheng WY
    World Neurosurg; 2019 Jun; 126():e41-e47. PubMed ID: 30716503
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of tumor characteristics and pre- and postoperative hormone levels on hormonal remission following endoscopic transsphenoidal surgery in patients with acromegaly.
    Cardinal T; Rutkowski MJ; Micko A; Shiroishi M; Jason Liu CS; Wrobel B; Carmichael J; Zada G
    Neurosurg Focus; 2020 Jun; 48(6):E10. PubMed ID: 32480366
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endoscopic endonasal transsphenoidal surgery for growth hormone-secreting pituitary adenomas.
    Hofstetter CP; Mannaa RH; Mubita L; Anand VK; Kennedy JW; Dehdashti AR; Schwartz TH
    Neurosurg Focus; 2010 Oct; 29(4):E6. PubMed ID: 20887131
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of pre-treatment with somatostatin analogs on surgical management of acromegalic patients referred to a single center.
    Bacigaluppi S; Gatto F; Anania P; Bragazzi NL; Rossi DC; Benvegnu G; Nazzari E; Spaziante R; Giusti M; Ferone D; Zona G
    Endocrine; 2016 Mar; 51(3):524-33. PubMed ID: 25982150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gross total resection or debulking of pituitary adenomas improves hormonal control of acromegaly by somatostatin analogs.
    Petrossians P; Borges-Martins L; Espinoza C; Daly A; Betea D; Valdes-Socin H; Stevenaert A; Chanson P; Beckers A
    Eur J Endocrinol; 2005 Jan; 152(1):61-6. PubMed ID: 15762188
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic Factors of Acromegalic Patients with Growth Hormone-Secreting Pituitary Adenoma After Transsphenoidal Surgery.
    Taweesomboonyat C; Oearsakul T
    World Neurosurg; 2021 Feb; 146():e1360-e1366. PubMed ID: 33309643
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes after a purely endoscopic transsphenoidal resection of growth hormone-secreting pituitary adenomas.
    Campbell PG; Kenning E; Andrews DW; Yadla S; Rosen M; Evans JJ
    Neurosurg Focus; 2010 Oct; 29(4):E5. PubMed ID: 20887130
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pure endoscopic transsphenoidal surgery for treatment of acromegaly: results of 67 cases treated in a pituitary center.
    Gondim JA; Almeida JP; de Albuquerque LA; Gomes E; Schops M; Ferraz T
    Neurosurg Focus; 2010 Oct; 29(4):E7. PubMed ID: 20887132
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Postoperative GH and Degree of Reduction in IGF-1 Predicts Postoperative Hormonal Remission in Acromegaly.
    Cardinal T; Collet C; Wedemeyer M; Singer PA; Weiss M; Zada G; Carmichael JD
    Front Endocrinol (Lausanne); 2021; 12():743052. PubMed ID: 34867787
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Short-term preoperative octreotide treatment of GH-secreting pituitary adenoma: predictors of tumor shrinkage.
    Oshino S; Saitoh Y; Kasayama S; Arita N; Ohnishi T; Kohara H; Izumoto S; Yoshimine T
    Endocr J; 2006 Feb; 53(1):125-32. PubMed ID: 16543682
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Surgical and Pharmacological Outcomes in Acromegaly: Real-Life Data From the Mexican Acromegaly Registry.
    Mercado M; Abreu C; Vergara-López A; González-Virla B; Espinosa-de-Los-Monteros AL; Sosa-Eroza E; Cadena-Obando D; Cuevas-Ramos D; Portocarrero-Ortiz LA; Pérez-Reyes SP; Mercado-Cherem A; Ibarra-Salce R; Talavera JO
    J Clin Endocrinol Metab; 2020 Dec; 105(12):. PubMed ID: 32944780
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Partial surgical removal of growth hormone-secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly.
    Colao A; Attanasio R; Pivonello R; Cappabianca P; Cavallo LM; Lasio G; Lodrini A; Lombardi G; Cozzi R
    J Clin Endocrinol Metab; 2006 Jan; 91(1):85-92. PubMed ID: 16263832
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prolonged preoperative treatment of acromegaly with Somatostatin analogs may improve surgical outcome in patients with invasive pituitary macroadenoma (Knosp grades 1-3): a retrospective cohort study conducted at a single center.
    Duan L; Zhu H; Xing B; Gu F
    BMC Endocr Disord; 2017 Sep; 17(1):55. PubMed ID: 28874187
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Presurgical treatment with somatostatin analogues in growth hormone-secreting pituitary adenomas: A long-term single-center experience.
    Lv L; Hu Y; Zhou P; Zhang S; Yin S; Zhang N; Jiang S
    Clin Neurol Neurosurg; 2018 Apr; 167():24-30. PubMed ID: 29433055
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of presurgical long-acting octreotide treatment in acromegaly patients with invasive pituitary macroadenomas: a prospective randomized study.
    Shen M; Shou X; Wang Y; Zhang Z; Wu J; Mao Y; Li S; Zhao Y
    Endocr J; 2010; 57(12):1035-44. PubMed ID: 21099129
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A single-center experience of transsphenoidal endoscopic surgery for acromegaly in 73 patients: results and predictive factors for remission.
    Unal TC; Aydoseli A; Ozgen U; Dolas I; Sabanci PA; Aras Y; Ozturk M; Ozata MS; Gul N; Kubat Uzum A; Mutlu U; Bilgic B; Saka E; Yarman S; Sencer A
    Br J Neurosurg; 2024 Jun; 38(3):648-653. PubMed ID: 34241568
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aggressive transsphenoidal resection of tumors invading the cavernous sinus in patients with acromegaly: predictive factors, strategies, and outcomes.
    Nishioka H; Fukuhara N; Horiguchi K; Yamada S
    J Neurosurg; 2014 Sep; 121(3):505-10. PubMed ID: 25014437
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Growth hormone-secreting macroadenoma of the pituitary gland successfully treated with the radiolabeled somatostatin analog (90)Y-DOTATATE: case report.
    Waligórska-Stachura J; Gut P; Sawicka-Gutaj N; Liebert W; Gryczyńska M; Baszko-Błaszyk D; Blanco-Gangoo AR; Ruchała M
    J Neurosurg; 2016 Aug; 125(2):346-9. PubMed ID: 26636388
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SIGNIFICANT ELEVATION OF GROWTH HORMONE LEVEL IMPACTS SURGICAL OUTCOMES IN ACROMEGALY.
    Anthony JR; Alwahab UA; Kanakiya NK; Pontell DM; Veledar E; Oyesiku NM; Ioachimescu AG
    Endocr Pract; 2015 Sep; 21(9):1001-9. PubMed ID: 26121434
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of preoperative pasireotide therapy on invasive octreotide-resistant acromegaly.
    Yamamoto R; Robert Shima K; Igawa H; Kaikoi Y; Sasagawa Y; Hayashi Y; Inoshita N; Fukuoka H; Takahashi Y; Takamura T
    Endocr J; 2018 Oct; 65(10):1061-1067. PubMed ID: 30078825
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.